CML
Haematology · 2007–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| asciminib Addition of nurse practitioners as eligible prescribers for continuing treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic or… | Mar 2026 | Recommended with restriction | 2 individuals |
| asciminib Treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase who have been previously treated with two or… | Jul 2022 | Not recommended | input received Leukaemia Foundation · Leukemia Foundation · Rare Cancers Australia |
| asciminib Treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase who have been previously treated with two or… | Nov 2022 | Recommended with restriction | none received |
| ponatinib Treatment of chronic myeloid leukaemia (CML) in patients with T315I mutation who have failed prior therapy, or in patients where both nilotinib and dasatinib… | Nov 2018 | Recommended with restriction | none received |
| dasatinib First-line treatment of patients with chronic myeloid leukaemia in the chronic phase. | Jul 2016 | Recommended with restriction | 3 individuals |
| ponatinib Treatment of adult patients with chronic myeloid leukaemia (CML) who have failed second-line TKI therapy or have the T315I mutation, and relapsed or refractory… | Jul 2015 | Recommended with restriction | 2 individuals |
| dasatinib Amendment to first-line PBS restriction for chronic myeloid leukaemia (CML) chronic phase to allow second and subsequent Authority required applications to be… | Jul 2014 | Not recommended | none received |
| dasatinib Treatment of newly diagnosed patients in the chronic phase of chronic myeloid leukaemia (CML) expressing the Philadelphia chromosome or bcr-abl tyrosine kinase. | Jul 2011 | Recommended with restriction | unclear |
| nilotinib First-line treatment of newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP). | Jul 2011 | Recommended with restriction | unclear |
| nilotinib Chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukaemia (CML) in adult patients intolerant of, or resistant to at least… | Mar 2008 | Recommended with restriction | no section in document |
| dasatinib Treatment of all phases of chronic myeloid leukaemia (CML) in adult patients expressing the Philadelphia chromosome or transcript, bcr-abl tyrosine kinase, who… | Mar 2007 | Recommended with restriction | no section in document |
| dasatinib Treatment of all phases of chronic myeloid leukaemia (CML) in adult patients expressing the Philadelphia chromosome or transcript, bcr-abl tyrosine kinase, who… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Leukaemia Foundation · Leukemia Foundation · Rare Cancers Australia
What the PBS pays
$108M in government benefit over 2024–25, across 44,963 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| asciminib | $27.3M |
| Dasatinib | $25.6M |
| dasatinib | $25.6M |
| nilotinib | $24.6M |
| ponatinib | $5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 6 technologies for this condition, recommending 5 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| asciminibAsciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | recommended restricted | 2022-08 |
| bosutinibBosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | terminated | 2019-04 |
| dasatinib nilotinib and high dose imatinibDasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | recommended restricted | 2016-12 |
| dasatinib nilotinib and imatinibDasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | recommended restricted | 2016-12 |
| bosutinibBosutinib for previously treated chronic myeloid leukaemia | TA401 | recommended | 2016-08 |
| guidance on the use of imatinibGuidance on the use of imatinib for chronic myeloid leukaemia | TA70 | recommended | 2003-10 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| busulfanAPO-Busulfan busulfan 60mg/10mL injection vial | 1999 | 7 |
| mitozantroneMITOZANTRONE EBEWE mitozantrone (as hydrochloride) 10mg/5mL solution f | 2001 | 6 |
| hydroxycarbamideHYDREA hydroxycarbamide 500 mg capsule bottle | 1994 | 3 |
| bosutinibBOSULIF bosutinib 100 mg tablet blister pack | 2014 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.